Literature DB >> 25646026

Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.

Eleonora Duregon1, Adele Cassenti1, Alessandra Pittaro1, Laura Ventura1, Rebecca Senetta1, Roberta Rudà1, Paola Cassoni1.   

Abstract

BACKGROUND: Mitotic count on hematoxylin and eosin (H&E)-stained slides is a crucial diagnostic criterion in meningioma grading. However, mitosis assessment on H&E slides can be impaired by technical factors and by pathologist's experience. Phosphohistone H3 (PHH3) serine-10 is a mitosis-specific antibody that has proven to facilitate mitotic count in various tumors.
METHODS: A series of 70 meningiomas (15 grade I, 40 grade II, 15 grade III) was used to validate PHH3 intra- and interobserver reproducibility and to identify PHH3-specific mitotic thresholds. Four pathologists with different experience in neuropathology counted mitoses on both H&E- and PHH3-stained slides.
RESULTS: H&amp;E and PHH3 mitotic rates were highly correlated (Pearson's r = 0.92, P < .0001). PHH3 mitotic counts had both a good mean interobserver correlation (R(m) = 0.83) and a good intraclass correlation (0.78), higher than H&amp;E mitotic indices (R(m) = 0.77, intraclass correlation = 0.71). After further stratification of meningiomas according to World Health Organization grade, PHH3 performed better in terms of interobserver concordance (Kendall's W = 0.761) compared with H&amp;E (Kendall's W = 0.697). Referring to the same meningioma groups identified by World Health Organization grade as the gold standard, the volume under the receiver operator characteristic surface was 0.91, indicating a very good diagnostic ability of PHH3 scores in discriminating the 3 meningioma groups. The 2 optimal PHH3-specific cutoff values were 6.61 and 22.02.
CONCLUSION: PHH3 staining is a useful diagnostic complementary tool to standard H&amp;E mitotic count, optimizing intra- and interobserver reproducibility. PHH3-specific mitotic thresholds should be adopted to avoid overgrading of meningioma when ancillary methods are employed.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  PHH3; cutoff; meningioma; mitotic count

Mesh:

Substances:

Year:  2015        PMID: 25646026      PMCID: PMC4482862          DOI: 10.1093/neuonc/nov002

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  49 in total

1.  Phosphorylated histone H3, Ki-67, p21, fatty acid synthase, and cleaved caspase-3 expression in benign and atypical granular cell tumors.

Authors:  Payal Kapur; Dinesh Rakheja; Jyoti P Balani; Lonnie C Roy; Robin H Amirkhan; Mai P Hoang
Journal:  Arch Pathol Lab Med       Date:  2007-01       Impact factor: 5.534

2.  Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.

Authors:  Yoo-Jin Kim; Ralf Ketter; Wolf-Ingo Steudel; Wolfgang Feiden
Journal:  Am J Clin Pathol       Date:  2007-07       Impact factor: 2.493

3.  Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis.

Authors:  G Juan; F Traganos; W M James; J M Ray; M Roberge; D M Sauve; H Anderson; Z Darzynkiewicz
Journal:  Cytometry       Date:  1998-06-01

4.  Three-way ROCs.

Authors:  D Mossman
Journal:  Med Decis Making       Date:  1999 Jan-Mar       Impact factor: 2.583

5.  Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa.

Authors:  Sven Gunia; Christoph Kakies; Andreas Erbersdobler; Stefan Koch; Matthias May
Journal:  J Clin Pathol       Date:  2012-05-03       Impact factor: 3.411

6.  Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma.

Authors:  Eleonora Duregon; Luca Molinaro; Marco Volante; Laura Ventura; Luisella Righi; Stefania Bolla; Massimo Terzolo; Anna Sapino; Mauro G Papotti
Journal:  Mod Pathol       Date:  2014-01-17       Impact factor: 7.842

7.  Immunohistochemical assessment of mitotic count in uveal melanoma.

Authors:  Martina Angi; Bertil Damato; Helen Kalirai; Andrew Dodson; Azzam Taktak; Sarah E Coupland
Journal:  Acta Ophthalmol       Date:  2011-03       Impact factor: 3.761

8.  Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Authors:  Rita G Ladstein; Ingeborg M Bachmann; Oddbjørn Straume; Lars A Akslen
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

9.  Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study.

Authors:  Emanuela Veras; Anais Malpica; Michael T Deavers; Elvio G Silva
Journal:  Int J Gynecol Pathol       Date:  2009-07       Impact factor: 2.762

10.  pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant.

Authors:  A Brunner; P Riss; G Heinze; H Brustmann
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

View more
  16 in total

1.  Phosphohistone H3: implications for clinical practice and risk assessment in meningioma.

Authors:  Adriana Olar
Journal:  Neuro Oncol       Date:  2015-03-25       Impact factor: 12.300

2.  Accurate likelihood inference for the volume under the ROC surface.

Authors:  Erlis Ruli; Laura Ventura
Journal:  Cancer Rep (Hoboken)       Date:  2019-12-10

Review 3.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

4.  Clinical and histopathological predictors of outcome in malignant meningioma.

Authors:  Andrea D Maier; Jiri Bartek; Frank Eriksson; Heidi Ugleholdt; Marianne Juhler; Helle Broholm; Tiit I Mathiesen
Journal:  Neurosurg Rev       Date:  2019-03-13       Impact factor: 3.042

5.  Role of proliferative marker index and KBTBD4 mutation in the pathological diagnosis of pineal parenchymal tumors.

Authors:  Eita Uchida; Atsushi Sasaki; Mitsuaki Shirahata; Tomonari Suzuki; Jun-Ichi Adachi; Kazuhiko Mishima; Masanori Yasuda; Takamitsu Fujimaki; Koichi Ichimura; Ryo Nishikawa
Journal:  Brain Tumor Pathol       Date:  2022-01-09       Impact factor: 3.298

6.  Can PPH3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors?

Authors:  Clotilde Dumars; Fanny Foubert; Yann Touchefeu; Nicolas Regenet; Hélène Senellart; Tamara Matysiak-Budnik; Marie-Françoise Heymann
Journal:  Endocrine       Date:  2016-04-05       Impact factor: 3.633

7.  Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas.

Authors:  Ping Zhu; Chuan-Bao Zhang; Pei Yang; Jing Chen; Yu-Qing Liu; Hui-Min Hu; Hua Huang; Zhao-Shi Bao; Wei Zhang; Wei-Jia Kong; Tao Jiang
Journal:  Oncotarget       Date:  2016-07-19

8.  The novel protein C9orf116 promotes rat liver cell line BRL-3A proliferation.

Authors:  Chunyan Zhang; Cuifang Chang; Weiming Zhao; Hang Gao; Qiwen Wang; Deming Li; Fuchun Zhang; Shifu Zhang; Cunshuan Xu
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

9.  Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.

Authors:  Eleonora Duregon; Luca Bertero; Alessandra Pittaro; Riccardo Soffietti; Roberta Rudà; Morena Trevisan; Mauro Papotti; Laura Ventura; Rebecca Senetta; Paola Cassoni
Journal:  Oncotarget       Date:  2016-04-19

10.  Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series.

Authors:  Luca Bertero; Vittorio Anfossi; Simona Osella-Abate; Maria Giulia Disanto; Cristina Mantovani; Francesco Zenga; Roberta Rudà; Diego Garbossa; Riccardo Soffietti; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.